[Endothelial function and cellular morphology and functionality inischemic limbs during drug therapy of obliterative atherosclerosis].
The aim of the study was to develop a rationale for Vasaprostan monotherapy of ischemia in patients with obliterative lesions in lower limb arteries. The assessment of blood cell ultrastructure revealed deformation of erythrocytes and platelets, aggregation of platelets and platelets with red cells, evidencing severe rheological alterations and increased incidence of thrombotic events in patients with critical ischemia. Vasaprostan monotherapy was more effective then combined therapy without prostaglandin E1. In patients with lower limb occlusive arterial lesions and different ischemic grades Vasaprostan alleviated endothelial dysfunction and normalized different morphological and functional parameters of erythrocytes and platelets. The trend toward ultrastructural normalization was evident in all patients after Vasaprostan administration. This trend was proved by changes in elemental composition of erythrocytes.


CONCLUSIONS
Vasaprostan is beneficial for patients with obliterative lesions in lower limb arteries and can be used as monotherapy or preoperative management for stimulation of volumetric blood flow and blood supply of ischemic tissues.
Katelnitskiĭ
I I
II
Rostov State Medical University, Rostov-on-Don, Russia. katelnizkji@mail.ru
Pleskachev
S A
SA
Katelnitskiĭ
I I
II
Matsionis
A S
AS
Povilaĭtite
P E
PE
D050197:Atherosclerosis / Q000150:complications* / Q000188:drug therapy; D001792:Blood Platelets / Q000648:ultrastructure; D004730:Endothelium, Vascular / Q000503:physiopathology* / Q000648:ultrastructure*; D004907:Erythrocyte Deformability / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects / Q000648:ultrastructure; D006801:Humans; D007511:Ischemia / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D007866:Leg / Q000098:blood supply*; D008854:Microscopy, Electron; D010974:Platelet Aggregation / Q000187:drug effects; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents